U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 186 results

Status:
US Approved Rx (2021)
First approved in 2009

Class (Stereo):
CHEMICAL (ABSOLUTE)



Everolimus is a derivative of Rapamycin (sirolimus), it is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the acti...
Status:
US Approved Rx (2016)
First approved in 2009

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pitavastatin is a new synthetic 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG-CoA reductase) inhibitor, which was developed, and has been available in Japan since July 2003. Metabolism of pitavastatin by the cytochrome P450 (CYP) system is mi...
Status:
US Approved Rx (2023)
First approved in 2009

Class (Stereo):
CHEMICAL (MIXED)



Saxagliptin is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatm...
Status:
US Approved Rx (2023)
First approved in 2009

Class (Stereo):
CHEMICAL (ACHIRAL)



Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious...
Status:
US Approved Rx (2022)
First approved in 2008

Class (Stereo):
CHEMICAL (ACHIRAL)



Etravirine (formerly known as TMC125) is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immuno...
Status:
US Approved Rx (2007)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Nilotinib (AMN107, trade name Tasigna) is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior ...
Status:
US Approved Rx (2024)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the monohydrate of the ditosylate salt (trade name TYKERB). Lapatinib is dual inhibitor of the EGFR (epidermal growth factor receptor...
Status:
US Approved Rx (2011)
First approved in 2007

Class (Stereo):
CHEMICAL (ACHIRAL)



Raltegravir (RAL, Isentress, formerly MK-0518) is an antiretroviral drug produced by Merck & Co., used to treat HIV and it is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients 4 weeks of ag...
Status:
US Approved Rx (2018)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a ...
Status:
US Approved Rx (2007)
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)



Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity ...